Downregulation of p16ink4a inhibits cell proliferation and induces G1 cell cycle arrest in cervical cancer cells

Zhang,Chu-Yue; Bao,Wei; Wang,Li-Hua

doi:10.3892/ijmm.2014.1731

Downregulation of p16ink4a inhibits cell proliferation and induces G1 cell cycle arrest in cervical cancer cells

Authors:
- Chu-Yue Zhang
- Wei Bao
- Li-Hua Wang
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, International Peace Maternity and Child Health Hospital of China Welfare Institute, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, P.R. China
Published online on: April 7, 2014 https://doi.org/10.3892/ijmm.2014.1731
Pages: 1577-1585

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Studies have suggested that p16ink4a may be a surrogate biomarker for the diagnosis of cervical cancer; however, the function of p16ink4a in human cervical cancer cells remains largely unknown. Therefore, in this study, we aimed to investigate the role of p16ink4a in human cervical cancer cells. Immunocytochemistry was used to examine invasive squamous cell carcinoma and its precancerous lesions. p16ink4a-siRNA was transfected into SiHa and HeLa cells to deplete its expression. The cellular levels of p16ink4a mRNA and protein were detected by qRT-PCR and western blot analysis. Proliferation rates were assessed by methyl thiazolyl tetrazolium (MTT) and plate colony formation assays. Cellular migration and invasion ability were assessed by a wound healing assay and Transwell assay. Cellular apoptosis and the cell cycle were measured by flow cytometry. The protein levels of retinoblastoma (Rb), phosphorylated Rb (phospho-Rb), cyclin D1 and caspase-3 were determined by western blot analysis. The results revealed that p16ink4a was overexpressed in the cervical cancer and precancerous lesions (P<0.05). The downregulation of p16ink4a in the SiHa and HeLa cells inhibited their proliferation, migration and invasion. In the SiHa cells, p16ink4a-siRNA also induced G1 cell cycle arrest and apoptosis. Western blot analysis revealed that the downregulation of p16ink4a in the SiHa cells markedly induced caspase-3 activation and decreased cyclin D1 expression. These data suggest that the overexpression of p16ink4a appears to be useful in monitoring cervical precancerous lesions, which supports that the hypothesis that p16ink4a is a surrogate biomarker for the diagnosis of cervical cancer. The therapeutic targeting of overexpressed p16ink4a in the p16ink4a-cyclin-Rb pathway may be a useful strategy in the treatment of cervical cancer.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
3	Mayrand MH, Duarte-Franco E, Rodrigues I, et al: Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 357:1579–1588. 2007. View Article : Google Scholar : PubMed/NCBI
4	Gustafsson L, Pontén J, Zack M and Adami HO: International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control. 8:755–763. 1997. View Article : Google Scholar : PubMed/NCBI
5	Kent A: HPV vaccination and testing. Rev Obstet Gynecol. 3:33–34. 2010.
6	Wang Y, Chen J, Zhang W, Hong W and Yu F: Study of the prevalence of human Papillomavirus infection in Chinese women with cervical cancer. Afr J Microbiol Res. 6:1048–1053. 2012.
7	Mathew A and George PS: Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix-worldwide. Asian Pac J Cancer Prev. 10:645–650. 2009.PubMed/NCBI
8	Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
9	Kool J, Uren AG, Martins CP, et al: Insertional mutagenesis in mice deficient for p15Ink4b, p16Ink4a, p21Cip1, and p27Kip1 reveals cancer gene interactions and correlations with tumor phenotypes. Cancer Res. 70:520–531. 2010. View Article : Google Scholar : PubMed/NCBI
10	Duan J, Chen Z, Liu P, Zhang Z and Tong T: Wild-type p16ink4a suppresses cell growth, telomerase activity and DNA repair in human breast cancer MCF-7 cells. Int J Oncol. 24:1597–1605. 2004.PubMed/NCBI
11	Yang CT, You L, Lin YC, Lin CL, Mccormick F and Jablons DM: A comparison analysis of anti-tumor efficacy of adenoviral gene replacement therapy (p14ARF and p16INK4A) in human mesothelioma cells. Anticancer Res. 23:33–38. 2003.PubMed/NCBI
12	Wu Q, Possati L, Montesi M, et al: Growth arrest and suppression of tumorigenicity of bladder-carcinoma cell lines induced by the P16/CDKN2 (p16INK4A, MTS1) gene and other loci on human chromosome 9. Int J Cancer. 65:840–846. 1996. View Article : Google Scholar : PubMed/NCBI
13	Martin CM and O’Leary JJ: Histology of cervical intraepithelial neoplasia and the role of biomarkers. Best Pract Res Clin Obstet Gynaecol. 25:605–615. 2011. View Article : Google Scholar : PubMed/NCBI
14	Klaes R, Friedrich T, Spitkovsky D, et al: Overexpression of p16 (INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 92:276–284. 2001. View Article : Google Scholar
15	Murphy N, Ring M, Heffron CC, et al: p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer. J Clin Pathol. 58:525–534. 2005. View Article : Google Scholar : PubMed/NCBI
16	Wentzensen N, Bergeron C, Cas F, Eschenbach D, Vinokurova S and von Knebel Doeberitz M: Evaluation of a nuclear score for p16INK4a-stained cervical squamous cells in liquid-based cytology samples. Cancer. 105:461–467. 2005. View Article : Google Scholar : PubMed/NCBI
17	Bao W, Qiu H, Yang T, et al: Upregulation of TrkB promotes epithelial-mesenchymal transition and anoikis resistance in endometrial carcinoma. PLoS One. 8:e706162013. View Article : Google Scholar : PubMed/NCBI
18	Peto J, Gilham C, Fletcher O, et al: The cervical cancer epidemic that screening has prevented in the UK. Lancet. 364:249–256. 2004. View Article : Google Scholar : PubMed/NCBI
19	Cuzick J, Arbyn M, Sankaranarayanan R, et al: Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 26(Suppl 10): K29–K41. 2008. View Article : Google Scholar : PubMed/NCBI
20	Yoshida T, Fukuda T, Sano T, et al: Usefulness of liquidbased cytology specimens for the immunocytochemical study of p16 expression and human papillomavirus testing: a comparative study using simultaneously sampled histology materials. Cancer. 102:100–108. 2004. View Article : Google Scholar
21	Kerr JF, Wyllie AH and Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 26:239–257. 1972. View Article : Google Scholar : PubMed/NCBI
22	Evan G and Littlewood T: A matter of life and cell death. Science. 281:1317–1322. 1998. View Article : Google Scholar : PubMed/NCBI
23	Molinari M: Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif. 33:261–274. 2000. View Article : Google Scholar : PubMed/NCBI
24	Liu W, Lv G, Li Y, Li L and Wang B: Downregulation of CDKN2A and suppression of cyclin D1 gene expressions in malignant gliomas. J Exp Clin Cancer Res. 30:762011. View Article : Google Scholar : PubMed/NCBI
25	Zadeh MD, Amini R, Firoozray M and Derakhshandeh-Peykar P: Frequent homozygous deletion of p16/CDKN2A gene in malignant gliomas of Iranian patients. Pak J Biol Sci. 10:4246–4250. 2007. View Article : Google Scholar : PubMed/NCBI
26	Kraus JA, Glesmann N, Beck M, et al: Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. J Neurooncol. 48:89–94. 2000. View Article : Google Scholar : PubMed/NCBI
27	Bignell GR, Greenman CD, Davies H, et al: Signatures of mutation and selection in the cancer genome. Nature. 463:893–898. 2010. View Article : Google Scholar : PubMed/NCBI
28	Beroukhim R, Mermel CH, Porter D, et al: The landscape of somatic copy-number alteration across human cancers. Nature. 463:899–905. 2010. View Article : Google Scholar : PubMed/NCBI
29	Anders L, Ke N, Hydbring P, Choi YJ, et al: A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell. 20:620–634. 2011. View Article : Google Scholar : PubMed/NCBI
30	Yu Q, Sicinska E, Geng Y, et al: Requirement for CDK4 kinase function in breast cancer. Cancer Cell. 9:23–32. 2006. View Article : Google Scholar : PubMed/NCBI
31	Puyol M, Martín A, Dubus P, et al: A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell. 18:63–73. 2010. View Article : Google Scholar : PubMed/NCBI